Lupin has received approval for its Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation. Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately $174 million in the U.S. (IQVIA MAT Sept ember 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
